Trial Profile
A Study to Evaluate the Safety and Efficacy of AT20-KLH Therapeutic Immunization in Clinically Asymptomatic HIV-1 Infected Patients Receiving HAART Therapy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Jan 2016
Price :
$35
*
At a glance
- Drugs AT20 KLH (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- Sponsors Medestea
- 06 Jan 2016 New trial record